Cleveland BioLabs, Inc.  

(Public, NASDAQ:CBLI)   Watch this stock  
Find more results for CBLI
-0.12 (-7.50%)
Oct 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.47 - 1.60
52 week 1.47 - 4.58
Open 1.55
Vol / Avg. 54,880.00/23,435.00
Mkt cap 16.68M
P/E     -
Div/yield     -
EPS -0.67
Shares 10.99M
Beta 1.05
Inst. own 4%
Nov 3, 2016
Q3 2016 Cleveland Biolabs Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 15, 2016
Q2 2016 Cleveland Biolabs Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -328.04% -481.68%
Operating margin -259.85% -398.45%
EBITD margin - -393.28%
Return on average assets -40.07% -85.00%
Return on average equity -86.78% -305.23%
Employees 16 -
CDP Score - -


73 High St
BUFFALO, NY 14203-1149
United States - Map
+1-716-8496810 (Phone)
+1-716-8496820 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company's programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5.

Officers and directors

Langdon L. Miller M.D. President and Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Yakov N. Kogan Ph.D. Chief Executive Officer, Director
Age: 41
Bio & Compensation  - Reuters
Andrei V. Gudkov Ph.D. Chief Scientific Officer, Director
Age: 58
Bio & Compensation  - Reuters
Alexander Andryushechkin Director
Bio & Compensation  - Reuters
Anna Evdokimova Director
Bio & Compensation  - Reuters
Konstantin Gorshkov Director
Bio & Compensation  - Reuters
Natalia Khudyk Director
Bio & Compensation  - Reuters
Tatiana Levina Director
Bio & Compensation  - Reuters